Brief: Market Capital Pleased With Aurinia's Commencement Of A Strategic Review Process
06/07/2023 13:15
July 6 (Reuters) - Aurinia Pharmaceuticals Inc AUPH.O :
* MARKET CAPITAL PLEASED WITH AURINIA’S COMMENCEMENT OF A
STRATEGIC REVIEW PROCESS
* MARKET CAPITAL LTD- BELIEVES AURINIA IS "IDEALLY
POSITIONED" TO
ACHIEVE A VALUE-MAXIMIZING SALE
* MARKET CAPITAL- URGES AURINIA TO REPLACE RESIGNING BOARD
MEMBERS
WITH SHAREHOLDER-DESIGNATED DIRECTORS EQUIPPED TO SUPPORT
COMPREHENSIVE REVIEW PROCESS
Source text for Eikon: ID:nBw7h7nT5a
Further company coverage: AUPH.O
((reuters.briefs@thomsonreuters.com;))
Recent news on Aurinia Pharmaceuticals
See all newsBrief: Aurinia Settles Patent Litigation With Teva
Canada's Aurinia Q2 revenue rises on LUPKYNIS sales
Brief: Aurinia Pharmaceuticals Q2 Pretax Profit USD 48.786 Million
Aurinia Pharmaceuticals Inc expected to post earnings of 24 cents a share - Earnings Preview
Brief: Lupkynis Associated With A Statistically Significant 53% Reduction In Risk Of Renal-Related Event Or Death